scispace - formally typeset
M

Meltem Elitas

Researcher at Sabancı University

Publications -  58
Citations -  663

Meltem Elitas is an academic researcher from Sabancı University. The author has contributed to research in topics: Motion control & Glioma. The author has an hindex of 11, co-authored 52 publications receiving 513 citations. Previous affiliations of Meltem Elitas include Yale University & École Polytechnique Fédérale de Lausanne.

Papers
More filters
Proceedings ArticleDOI

A Study on High Accuracy Discrete-Time Sliding Mode Control

TL;DR: In this article, a Discrete-Time Sliding-Mode based controller design for high accuracy motion control systems is presented, which is designed for a general SISO system with nonlinearity and external disturbance.
Journal ArticleDOI

Quantifying Deformation and Migration Properties of U87 Glioma Cells Using Dielectrophoretic Forces

TL;DR: In this article , a gold microelectrode array within a microfluidic channel and applied sinusoidal wave AC potential at 3 Vpp, ranging from 30 kHz to 10 MHz frequencies, to generate DEP forces.
Proceedings ArticleDOI

Optimization of U-Net: convolutional networks for U87 human glioblastoma cell line segmentation

TL;DR: U-Net algorithm is implemented for segmentation of U87 glioma cells and 0.06% loss and 97.3% accuracy values are obtained, which might contribute to development of automated, reliable, accurate, and cell type specific image segmentation tools.

loTs and Loop-Mediated Isothermal Amplification- Based Biosensing using Cloud-Enabled Features

TL;DR: In this paper, the authors implemented a cloud service to their LAMP-based biosensor and transferred the obtained image and results of the assays through cloud, which simplifies the data processing, it directly digitized the readouts and eliminates the need of data interpretation.
Journal ArticleDOI

Quantitative Investigation into the influence of intravenous fluids on human immune and cancer cell lines.

TL;DR: The impact of commonly used IVFs, Dextrose, NaCl and Ringer on different human cancer and immune cell lines and the importance and necessity of developing optimal diluents not only for drug stability but also for patient benefits are supported.